Search clinical trials for: BI 690517 (Reference)

Total 2094 results

Boehringer Ingelheim

Completed

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 690517 in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim
IQVIA global CRO

Completed

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

Healthy

Germany
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
AnHeart Therapeutics Inc.

Completed

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Solid Tumors

United States
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Cancer | Tumor

United States, Spain, Canada, France
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Hypertension | Dyslipidemias

Korea, Republic of
OsciFlex LLC
University of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

Venous Stasis | Venous Thromboses

United States
Boehringer Ingelheim

Completed

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Diabetic Nephropathies

Spain, Germany, United Kingdom, France, Greece, Portugal, Sweden, Russian Federation, Denmark, Slovakia
Bristol-Myers Squibb

Completed

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Cancer

Japan
Dong-A Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

Infertility | Induction of Ovulation
The Affiliated Hospital of Qingdao University

Enrolling by invitation

Bioequivalence Study of Ezetimibe Tablets Under Fed Conditions in Healthy Subjects

Pharmacokinetics | Safety

China
Bristol-Myers Squibb

Completed

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Cancer

United States, France
Academisch Medisch Centrum - Universiteit van Amsterdam...
DexCom, Inc.

Completed

Factors in Accuracy Studies Influencing Measured CGM Performance. (FACT-CGM)

Diabetes Mellitus, Type 1

Netherlands
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Cancer

Switzerland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Bristol-Myers Squibb

Completed

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Non-Small-Cell Lung Carcinoma

Japan
JHP Pharmaceuticals LLC
Syneos Health

Unknown

Equivalence Study of Specificity of PPD (03)

Tuberculosis Infection

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Nutricia Research

Recruiting

Assessment of the Glycemic Responses to Nutritional Products (v2.0) (GLIN#2)

Glycemic Response

Canada
Sonova AG

Completed

Pre-calculation for Frequency Lowering With Hearing Devices

Frequency Lowering

Switzerland
UCSF Benioff Children's Hospital Oakland
Almond Board of California

Completed

Effects of Almond Intake on Atherogenic Lipoprotein Particles

Dyslipidemia | Obesity, Abdominal

United States
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Fundación Cardiovascular de Colombia

Completed

Continuous Supraglottic Aspiration in Intubated and Mechanically Ventilated Patients: the "SUPRAtube" Device (Supratube)

Aspiration Pneumonias

Colombia
National Research Centre for the Working Environment...
University of Southampton; University of Southern Denmark

Completed

Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians (IRMA)

Stress | Musculoskeletal Disorders

Denmark
Almirall, S.A.
Sciderm GmbH

Completed

Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test

Psoriasis

Germany
Asir John Samuel
Maharishi Markandeshwar International School, Mullana

Completed

Normative Reference Values of Equilibrium Coordination Test Among Children

Coordination Disorder, Developmental

India
Institut fur Diabetes Karlsburg GmbH

Completed

User Evaluation of BGM VGM77

Diabetes

Germany
National Research Centre for the Working Environment...
University of Southampton

Completed

Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load (IRMA10)

Stress | Musculoskeletal Disorders

Denmark
National Research Centre for the Working Environment...
University of Southern Denmark

Completed

Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function (VIMS03)

Neck Pain | Shoulder Pain | Rehabilitation | Scapular Dyskinesis | Muscle Activation

Denmark
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan

3

Subscribe